Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Debora Duro

Pediatric Gastroenterology Fort Lauderdale, FL Medical Doctor

NPI 1194716761 CMS profile 145167

1625 Se 3Rd Ave, Suite 635, Fort Lauderdale, FL 33316

Open in the dashboard

General payments

$25,918

34 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Debora Duro of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $25,918 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,704 6
2024 General $3,478 3
2023 General $230 1
2022 General $11,685 12
2021 General $75 1
2019 General $7,746 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debora Duro
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Debora Duro were reported at $2,704. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Debora Duro Pediatric Gastroenterology median Middle half National median
2019 $7,746 $131 $41–$311 $163
2020 $0 $79 $23–$223 $114
2021 $75 $104 $32–$321 $132
2022 $11,685 $125 $37–$331 $149
2023 $230 $169 $55–$440 $160
2024 $3,478 $196 $73–$563 $164
2025 $2,704 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius Kabi USA, LLC $10,442 11 payments
  2. Alcresta Therapeutics, Inc. $6,025 4 payments
  3. Shire North American Group Inc $5,733 8 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $3,471 5 payments
  5. Mirum Pharmaceuticals, Inc. $95 3 payments
  6. Intuitive Surgical, Inc. $90 1 payment
  7. CapsoVision, Inc. $41 1 payment
  8. Applied Medical Technology Inc $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,080 9 payments
  2. Honoraria $6,025 4 payments
  3. Travel and Lodging $923 5 payments
  4. Food and Beverage $890 16 payments
Products named General payments · program years 2019–2025
  1. Smoflipid $8,497 9 payments
  2. RELIZORB $6,025 4 payments
  3. GATTEX $4,256 7 payments
  4. PH-Omegaven $1,945 2 payments
  5. Livmarli $95 3 payments
  6. Da Vinci Surgical System $90 1 payment
  7. Entyvio $69 1 payment
  8. CHOLBAM $67 2 payments
  9. Chenodal $67 2 payments
  10. CapsoCam Plus $41 1 payment
  11. Other $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record